Currently, the global pharmaceutical industry is undergoing three profound transformations:
First, supply chain restructuring is accelerating. With the continued escalation of China–US trade frictions, coupled with the EU’s Pharmaceutical Strategy 2030 systematically promoting local capacity building, the global industry chain is being pushed toward “de-concentration.”
Second, technological revolutions are advancing. New technologies such as artificial intelligence (AI)-driven drug design and synthetic biology are reshaping R&D and production paradigms, making digital-intelligent transformation the key to breakthroughs.
Third, demand structures are shifting significantly. Emerging markets in Latin America and Southeast Asia are experiencing much faster pharmaceutical consumption growth than mature markets in Europe and the US, opening up a new blue ocean for Chinese innovative pharmaceuticals and medical devices going global.

Against this backdrop, the April 25, 2025 CPC Central Political Bureau meeting for the first time proposed to “use the certainty of high-quality development to address external uncertainty,” outlining a development path for innovative pharmaceuticals and devices characterized by “innovation-driven growth, diversified collaboration, and resilience as the foundation.”

Central Policy Orientation:

Three Breakthroughs from Strategic Blueprint to Industrial Practice

1. Digital-Intelligent Transformation: The Core Engine Reshaping Global Competitiveness

The Politburo meeting emphasized accelerating the “AI+” initiative. The Pharmaceutical Industry Digital-Intelligent Transformation Implementation Plan (2025–2030), jointly issued by seven ministries, sets a two-step goal: by 2027, build more than 100 digital-intelligent pharmaceutical and medical device factories; by 2030, achieve full-scale digital-intelligent transformation coverage across all large-scale pharmaceutical enterprises.

This strategy is already producing results across the pharmaceutical value chain:

  • R&D side: Insilico Medicine’s proprietary Chemistry42 platform, powered by reinforcement learning algorithms, shortened the lead compound optimization cycle by 78% to just 4 months, saving over RMB 30 million per project. Hengrui Pharmaceuticals’ R&D expenditure reached RMB 1.533 billion in Q1 2025, with cumulative R&D investment exceeding RMB 46 billion. Currently, the company has over 90 innovative products in clinical development and around 400 clinical trials worldwide.
  • Production side: Yangtze River Pharmaceutical Group is actively applying AI, big data, and cloud computing to achieve intelligent management across planting, production, and logistics. Its digital-intelligent upgrades have boosted production efficiency by 28% and output by 43%. Fosun Pulse has announced plans to establish seven AI-based medical device product pipelines in Chongqing, supporting “smart healthcare” construction.
  • Supply chain side: Jointown Pharmaceutical Group’s TCM traceability system has been recognized as a national-level benchmark case for digital transformation. Its medical supplies digital platform, “Ten-Thousand Stores” initiative, and Smart TCM platform have won national and provincial awards. Huahai Pharmaceutical has built a robust multi-channel marketing system in the US, covering self-operated sales, wholesalers, retail chains, and commercial companies, reaching 95% of the generic drug market’s major buyers.

2. Market Diversification: A Strategic Choice to Overcome Geopolitical Barriers

The meeting stressed “unswervingly expanding high-level opening-up” and highlighted the importance of balancing domestic economic work with international trade frictions. Chinese pharmaceutical companies are pursuing a dual strategy of “deepening traditional markets + expanding emerging markets.”

  • Belt and Road Initiative as a growth driver: According to data compiled by the China Chamber of Commerce for Import & Export of Medicines & Health Products, from January to March 2025, exports of medicines to 64 Belt and Road countries reached USD 8.745 billion (up 4.15% YoY). Exports to the Eurasian Economic Union (5 countries) totaled USD 1.005 billion (up 13.69%), and exports to the Arab League (22 countries) hit USD 1.08 billion (up 10.21%).
  • Breakthroughs in developed markets: Luye Pharma’s rotigotine patch was launched in the UK in 2025 for the treatment of signs and symptoms of early and advanced idiopathic Parkinson’s disease and moderate-to-severe idiopathic Restless Legs Syndrome. It is the first generic of Neupro® in the UK, with proven bioequivalence. Meanwhile, Mindray’s Q3 2024 report showed its medical imaging business generated RMB 5.97 billion, up 11.4% YoY, with European market growth exceeding 30%.

3. Supply Chain Resilience: The Fundamental Logic of Industrial Security

In response to the US “Critical Medicine Supply Chain Reshoring” plan, China is strengthening its “chain leader system” strategy:

  • API upgrading: China plays a critical role globally in the production of penicillin industrial salts, vitamins, and sartans intermediates. The focus is now on moving toward higher-value APIs. For example, Tonghe Pharma’s valsartan potassium API has obtained drug registration in South Korea and filed six registrations in the US and Canada. Jiuzhou Pharma’s peptide API plant in Suzhou began its Phase II capacity expansion in 2025, scheduled for commercial launch in September 2025, with plans to build six GMP peptide production lines within five years, breaking the US/EU monopoly.
  • Bi-directional circulation of innovative drugs and devices: BeiGene’s Brukinsa® (zanubrutinib) obtained approvals in both China and the US through a “dual-filing” strategy. In Q1–Q3 2024, US revenue accounted for 73.5% of global sales, while China accounted for 10.5%. MicroPort’s Firebird coronary stent has been implanted in over 500,000 patients across Belt and Road countries, while the company is also introducing Israel’s Galmed NASH drug into Chinese clinical development, forming a closed-loop of “technology introduction–localization–global output.”

Tackling External Uncertainty:

Precise Alignment of Three Major Challenges with Targeted Strategies

1. Tariff Barriers and Technology Blockades: From “Cost Game” to “Value Breakthrough”

  • Upgrading product structure: Shifting away from low-value “red ocean” products and focusing on new tracks such as biologics and cell therapies. For instance, CAR-T therapies (such as Legend Biotech’s CARVYKTI®), which involve complex gene editing and cell culture processes, deliver high added value.
  • Leveraging regional trade agreements: To hedge US policy risks, Chinese firms are tapping into RCEP’s rules of origin cumulation, accelerating Southeast Asia expansion while deepening presence in Europe, the Middle East, and Latin America. Through regulatory registration, channel development, and brand building, they are establishing balanced global sales networks to effectively diversify risks.

2. International Regulatory Compliance: From “Passive Adaptation” to “Rule Co-Creation”

  • Breakthroughs in TCM standard internationalization: For example, the China Academy of Chinese Medical Sciences and Guangxi Botanical Garden of Medicinal Plants supported Laos in compiling the Pharmacopoeia of Laos, balancing local traditions with Chinese expertise. In Southeast Asia and Latin America, some countries are beginning to adopt TCM standards from the Chinese Pharmacopoeia. Canadian authorities have also initiated talks to recognize certain TCM entries. These moves reflect growing international recognition of Chinese pharmaceutical standards.
  • Building full-process compliance capacity: In March 2025, WuXi AppTec’s API sites in Changzhou and Taixing both passed US FDA inspections with zero deficiencies, with no Form 483 observations issued.

3. Intellectual Property: From “Follow-On Innovation” to “Original Innovation Leadership”

For instance, as of April 2025, Ascentage Pharma held 541 authorized patents, including 379 overseas patents covering major global markets. Hengrui Pharmaceuticals filed 45 international patents in the PD-1 monoclonal antibody field, with its camrelizumab entering markets such as Turkey and Egypt through “patent licensing + localized manufacturing.”

Deep Breakthroughs in High-Quality Development:

From “Scale Expansion” to “Value Leadership”

1. Internationalization of Traditional Chinese Medicine: From “Cultural Export” to “Standards Export”

  • Policy measures: The Implementation Plan for Major Projects of Revitalization and Development of Traditional Chinese Medicine specifies establishing 50 overseas TCM centers and releasing 50 international standards during the 14th Five-Year Plan. The Ministry of Commerce’s TCM Service Export Bases now cover 32 countries, serving over 2 million people annually.
  • Technology empowerment: For example, Yunnan Baiyao used “phytochemistry-based metabolomics + network pharmacology” to raise the purity of Panax notoginseng saponins to 98%, overcoming the EU’s uniformity-of-content hurdle for herbal medicine registration.

2. Global R&D Networks: From “Local Enterprises” to “Multinational Corporations”

  • Dual-headquarter model rising: BeiGene operates R&D centers in both China and the US, conducting international Phase III trials in parallel under a “Shanghai by day, Boston by night” 24-hour relay model. Zai Lab set up a translational medicine center in London to rapidly access European clinical trial resources.
  • Cross-border innovation ecosystems: Suzhou BioBAY has established offshore innovation hubs in Singapore and Boston, creating a loop of “R&D overseas, translation in Suzhou, global markets.” It has already incubated more than 10 firms, including Innovent Biologics and Keymed Biosciences.

3. Green and Low-Carbon Transformation: A New Threshold for Global Competition

  • Harbin Pharmaceutical Group (Hayao): In its 2025 Quality and Efficiency Enhancement for Sustainable Returns plan, the company proposed building a green industrial chain through digital-intelligent production and cost control. In April, Sanjing Pharmaceutical signed a deal with Jiuzhou Group for a distributed photovoltaic project in Daqing, advancing low-carbon transition through solar energy.
  • Qilu Pharmaceutical (Hainan): Using Qilu’s integrated energy management platform, a single three-stage heat-exchange freeze dryer saves over 200,000 kWh annually. The upgraded water purification system achieved a 90% recovery rate, saving over 10,000 tons of water annually.

Conclusion: Building New Advantages through Dynamic Balance

By consolidating innovation engines through digital-intelligent transformation, diversifying markets to mitigate risks, and strengthening supply chain resilience against shocks, China’s innovative pharmaceuticals and devices are harnessing the “three certainties” of high-quality development to counter the “three uncertainties” of global industrial chain restructuring.

Facing “tariff pressure + technological blockades + regulatory reshaping,” China’s pharmaceutical exports are moving from “factor-driven” to “efficiency-driven” and “innovation-driven.”

  • At the government level, China should accelerate TCM international standard-setting and enhance policy toolkits for digital-intelligent transformation.
  • At the enterprise level, firms should build resilient systems of “globalized R&D, localized production, diversified markets.”
  • At the industry level, leveraging free trade zones and cross-border innovation ecosystems is key to exploring integrated export models of “medicines + services” and “products + technologies.”

Looking ahead, only by embedding the “certainty” of high-quality development into innovation capacity, industrial resilience, and global collaboration can China firmly seize the strategic initiative in pharmaceutical and medical device globalization, contributing a genuine “China Solution” to the global health industry chain.